US20020156251A1 - Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine - Google Patents
Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine Download PDFInfo
- Publication number
- US20020156251A1 US20020156251A1 US09/319,264 US31926499A US2002156251A1 US 20020156251 A1 US20020156251 A1 US 20020156251A1 US 31926499 A US31926499 A US 31926499A US 2002156251 A1 US2002156251 A1 US 2002156251A1
- Authority
- US
- United States
- Prior art keywords
- protein
- cells
- cmv
- peptide
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 76
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 30
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 30
- 229960005486 vaccine Drugs 0.000 title description 9
- 241000701022 Cytomegalovirus Species 0.000 claims abstract description 33
- 102000007079 Peptide Fragments Human genes 0.000 claims abstract description 17
- 108010033276 Peptide Fragments Proteins 0.000 claims abstract description 17
- 239000002773 nucleotide Substances 0.000 claims abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 3
- 239000012634 fragment Substances 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 65
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 239000012636 effector Substances 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 230000009089 cytolysis Effects 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 7
- 229960003677 chloroquine Drugs 0.000 description 7
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 6
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 206010003571 Astrocytoma Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- 206010062343 Congenital infection Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010004141 HLA-B35 Antigen Proteins 0.000 description 3
- 108010086066 HLA-DR8 antigen Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101100476827 Bacillus subtilis (strain 168) scoA gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 102220515784 Nuclear receptor subfamily 0 group B member 2_N15K_mutation Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 101150081415 UL55 gene Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000004651 endocytosis pathway Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101150029683 gB gene Proteins 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to novel combinations of proteins and to their use as medicament. More particularly, it relates to the preparation of vaccines against CMV.
- CMV Human cytomegalovirus
- CMV protein pp65 or a fragment thereof with another hapten or antigen of CMV allows the immune reaction towards this virus to be potentiated, in particular by stimulating the compartments T CD4+ and CD8+ against the virus.
- the present invention relates to a fusion protein, characterized in that it comprises at least part of the cytomegalovirus (or CMV) protein pp65, or of a protein having at least 80% homology with protein pp65, in combination with at least one second peptide fragment derived from CMV.
- CMV cytomegalovirus
- Protein pp65 is a CMV matrix protein which is internalized in the cells and delivered into the cytosol at the same time as the virion, very shortly after infection.
- the peptide fragments which make up the chimeric protein preferably have a length of greater than, or equal to, 9 amino acids and cover different HLA class I restrictions.
- the applicant has shown that a peptide of protein pp65 of a length greater than 9 amino acids can be internalized by a presenting cell and presented to a CD8+ specific T-line by a class I MHC molecule.
- the importance of constructions which include these peptides and the protein IE1 for vaccination would be linked to the use of antigens which are capable of entering the presenting cell by a unique endocytosis pathway, simultaneously inducing it to a TCD4+ and TCD8+ response.
- the second peptide fragment which is present in the fusion protein is preferably composed of protein IE1 or one of its epitopes, or of a protein having at least 80% homology.
- the polypeptide sequence of IE1 which is a major regulatory protein of the viral cycle, is highly conserved between the different viral strains.
- Introduction of this protein into a subunit vaccine would allow the induction of memory CD4+ helper T-cells, which are capable of cooperating with the induction of cytotoxic CD8+ T-cells against pp65 and with the production of antibody against the envelope protein gB, subjected to greater variability (cross help).
- cross helper T-cells which are capable of cooperating with the induction of cytotoxic CD8+ T-cells against pp65 and with the production of antibody against the envelope protein gB, subjected to greater variability (cross help).
- gB the viral envelope glycoprotein
- fragment e4 of CMV protein IE1 or a peptide fragment having at least 80% homology with said fragment e4.
- e4, or exon 4 which comprises 406 amino acids, is a fragment of protein IE1, which is composed of 491 amino acids.
- the fusion protein comprises a) the fragment delimited by the amino acid residues 162 and 175 of the sequence of protein IE1, or
- epitopes are also suitable for carrying out the invention, such as those mentioned by Davignon et al. (8).
- the fusion protein according to the invention can additionally contain a peptide fragment derived from a microorganism other than CMV and/or any polypeptide fragment which allows it to be purified later from Tag-type sequences; these sequences, which are placed upstream or downstream of the protein of interest allow it to be purified or labeled; the use of ⁇ -galactosidase, histidine hexamers (His6) or GST may be mentioned as examples.
- the fusion protein comprises a peptide fragment derived from an enzyme with glutathion-S transferase (or GST) activity.
- the GST protein will make it easier, in particular, to purify the fusion protein from a complex culture medium.
- the invention therefore relates to a chimeric protein GST-IE1-pp65 of 145 kd, which can be prepared in E. coli. Its immunogenicity was demonstrated in vitro by the proliferation of IE1-specific CD4+ T-cell-clones and by the lysis of target cells incubated in the presence of a pp65-specific CD8+ T-line. The applicant has shown that the protein in soluble form and its fragments allow the CD4+ and CD8+ T-compartments of the specific cell response to be stimulated in vitro. These results make this protein the reactant of choice for designing a subunit vaccine.
- nucleotide sequences which code for a fusion protein as defined hereinabove are also within the scope of the invention.
- the fusion proteins and the corresponding nucleotide sequences can be used as medicament and in particular for the preparation of a vaccine for preventing infections caused by CMV.
- a vaccine will be suitable for inducing an efficient response against a primary infection before the virus has replicated actively.
- the invention relates to a pharmaceutical composition, characterized in that it contains
- compositions can contain immunity adjuvants. They can also contain other CMV epitopes. Finally, they can be formulated with systems which improve transport and presentation of the molecules to the target cells.
- the proteins can be in the form of various different proteins in the composition; they can also be in the form of a fusion protein as described above; the same applies to the corresponding nucleotide sequences.
- composition can contain other epitopes, in particular CMV envelope antigens, such as protein gB.
- the invention relates to a process for the preparation of a fusion protein, characterized in that the following steps are carried out:
- the host cell which contains a nucleotide sequence coding for a fusion protein which can be obtained in the process described hereinabove, also comes within the scope of the invention.
- This host cell can be selected in particular from the group consisting of the bacteria, the viruses, the yeasts and eukaryotic cells, in particular higher eukaryotes.
- FIG. 1 Western blot analysis of the expression of protein GST-IE1-pp65.
- Lysates of bacteria which have been transformed with plasmids pGEX 2TK (1) and PGEX 2TK/IE1-pp65 (2, 2′) were subjected to SDS-PAGE and then to a western blot which is visualized by antibodies against GST (A), against IE1 (B) and against pp65 (C).
- Pre-stained molecular weight markers (Gibco) have been used.
- FIG. 2 Protein GST-IE1-pp65 induces a specific proliferation of the CD4+ T-clone BeA3G9 in the presence of PBMC.
- FIG. 3 The anti-pp65 CD8+ T-line “Val” lysis of U373MG astrocytoma cells infected with CMV Towne.
- FIG. 4 Schematic representation of recombinant proteins produced in E. coli.
- FIG. 5 The anti-pp65 CD8+ T-line “Val” lysis of B/EBV cells incubated in the presence of the trypsin-pretreated protein GST-IE1-pp65.
- FIG. 6 Analysis of the production of the protein His6-IE1-pp65 by insect cells infected with a recombinant baculovirus.
- Sf9 insect cells were infected for 48 hours with recombinant IE1-pp65 baculoviruses.
- the cell lysates (1) were centrifuged, and the supernatant (2) was passed through an Ni-agarose column and the eluates were recovered (3, 4).
- the different fractions were subjected to SDS-PAGE and stained with Coomassie blue.
- FIG. 7 Induction of anti-IE1 CD4+ T-effectors in a CMV+ donor using formulation SMBV/IE1-pp65.
- PBMCs of a CMV+ donor were stimulated with the protein IE1-pp65 (AG) either in soluble form or formulated with SMBV (AG form) or in the absence of antigen (mock).
- AG protein IE1-pp65
- SMBV SMBV
- IE1 protein IE1
- pRL103 The region of the viral genome containing the sequence which codes for protein IE1 which is located in the Hind III C fragment of the CMV strain Towne was cloned into a plasmid called pRL103.
- This plasmid was used for transfecting cells of the astrocyte line U373 MG (termed A2 (provided by R. Lafemina, Merck Sharp and Dohme, WestPoint, Pa., USA). These cells were cultured to confluence in RPMI-FCS (RPMI 1640 Glutamax, 1 mM sodium pyruvate, 200 u/ml penicillin, 100 ⁇ g/ml streptomycin, 10% decomplemented calf serum).
- RPMI-FCS RPMI 1640 Glutamax, 1 mM sodium pyruvate, 200 u/ml penicillin, 100 ⁇ g/ml streptomycin, 10% decomplemented calf serum.
- the total RNA of a 3-day culture was prepared following the method of Chomzynski and Sacchi (14).
- the IEI cDNA was generated by RT-PCR (Kit Super Script, GIBCO BRL) using an aliquot of 5 ⁇ g of total RNA, in accordance with the manufacturer's instructions using the primers C1: GATCC GGATCC ATGGAGTCCTCTGCCAAGAGA and C2: CCCGGG GAATTC CTGGTCAGCCTTGCTTCTAGT. BamH1 and EcoR1 sites were introduced into the primers C1 (5′-end of IE1) and C2 (3′-end of IE1), respectively.
- the PCR product thus obtained (1480 bp) was purified on an S400-HR column (PHARMACIA).
- the virus particles were harvested by centrifugation (31,000 g, 4° C., 90 minutes) and the capsids were degraded by treatment with proteinase K (BOEHRINGER) (150 ⁇ g) in 250 ⁇ l lysis buffer (10 mM TrisCl pH 7.5, 1 mM EDTA, 2% sarcosyl) for 30 minutes at ambient temperature.
- the viral DNA was extracted with phenol/chloroform and then precipitated with absolute ethanol.
- the DNA pellet was dried and solubilized in 20 ⁇ l of water.
- a fragment corresponding to the pp65 cDNA was obtained by PCR with an aliquot of 2 ⁇ l of viral DNA using the primers C3: CCCGGG GAATTC ATGGCATCCGTACTGGGTCCC and C4: GAATTC GGATCC TCAACCTCGGTGCTrmGG which were complementary to the 5′ and 3′ ends of the pp65 gene and contained the EcoRI and BamHI sites, respectively.
- the PCR product (1670 bp) was purified on an S400-HR column (PHARMACIA).
- the IEI and pp65 cDNA fragments were previously cloned into the BamH1 and EcoRI sites of a pUC18 plasmid.
- Competent DH5 ⁇ bacteria (GIBCO) were transformed with 5 to 10 ng of a ligation IEI/pUC18 or pp65/pUC18.
- the recombinant plasmids were digested with BamH1 and EcoR1. The digestion products were separated by agarose gel electrophoresis and extracted from the gel using the “JetSorb/150” kit (GENOMED).
- Fragment IE1-pp65 was inserted into the BamH1 site of plasmid PGEX 2TK (PHARMACIA). Clones of the recombinant bacteria were stored at ⁇ 80° C. in PBS, 3.5% DMSO, until used for protein purification.
- the bacteria were lysed and the recombinant protein purified by affinity chromatography on a “Sepharose 4-B” column grafted with glutathion (PHARMACIA) according to the manufacturer's instructions.
- the degree of purity of the protein was checked by SDS-PAGE followed by staining with Coomassie blue.
- the antigenicity of GST-IE1-pp65 was analyzed by western blot using goat antibodies directed against GST (PHARMACIA, dilution 1/400), and mouse antibodies directed against IE1 (supernatant E13 diluted to 1/10, provided by Dr Mazeron, Hal Lariboisière, Paris) and pp65 (NEA 20 diluted to 1/250, DUPONT). Secondary antibodies coupled to RAG/PO, RAM/PO peroxidase (Nordic) were used at 1/500. The proteins were assayed by the method of Bradford using the “Bio-Rad Protein Assay” kit (BIORAD). The recombinant GST protein was produced and purified.
- Peripheral blood leukocytes of CMV-seropositive donors of the haplotype HLA-A2 were cultured in 24-well-plates in RPMI-SH (2 ml). On day 3, 100 U/ml of “Lymphocult-T-LF” (BIOTEST, France) were added. On day 7, the live cells were recovered in the ring of a ficoll gradient. These cells (5 ⁇ 10 5 /well) were incubated in the presence of autologous stimulator cells (1.5 ⁇ 10 6 /well) in RPMI-SH (2 ml) supplemented with 10% of “Lymphocult”.
- the stimulator cells (10 ⁇ 10 6 cells/ml) were incubated in RPMI in the presence of 30 ug of a peptide presented by HLA-A2 (peptide N9V, FIG. 5, Neosystem, France) for 1 hour at 37° C. and irradiated (2500 rads).
- the effector cells were restimulated under the same conditions every 7 days.
- the cytotoxicity of the resulting line “Val” was tested on day 14.
- the CD8+ phenotype of the line was determined cytofluorimetrically with the monoclonal mouse antibody OKT8.
- U373MG astrocytoma cells of the haplotype HLA-A2 (2 ⁇ 10 5 ) at 80% confluence in RPMI/FCS were infected with Towne-CMV virus at 5 pfu/cell in 6-well-plates (10 cm2). After infection for 4 hours, the cells were labeled with 100 ⁇ ci of Na 2 51 CrO 4 (ICN, France) and washed with RPMI.
- the autologous effector cells of the CD8+ T-line were incubated with 10 4 target cells in RPMI/10% FCS (500 ⁇ l) for 4 hours at 37° C.
- Various quantities of effector cells were added to the targets to obtain different effector/target ratios.
- the rate of spontaneous enlargement was determined by measuring the radioactivity liberated by target cells which were cultured for 4 hours. The percentage of specific lysis was calculated by using the following formula ([measured radioactivity ⁇ spontaneous enlargement/total radioactivity ⁇ spontaneous enlargement] ⁇ 100). The radioactivity is measured on a Cobra- ⁇ -counter (PACKARD). Each measurement is carried out in duplicate.
- III-2 In the presence of the native or trypsin—digested protein GST-IEI-pp65, with or without chloroquine
- the purified protein GST-IE1-pp65 was demineralized in an ultrafiltration centrifuge with “Centricon 10” filter units (FILTRON), lyophilized and taken up in water and then used in this form or digested with trypsin (TCPK, SIGMA, 200 ng per 900 ⁇ g of protein) in a volume of 100 ⁇ l of Tris-buffer [100 mM tris-HCl pH 8.0] for 2 hours at 370° C. Aliquots taken before and after digestion were analyzed by SDS-PAGE.
- the cells (50,000/ml) were labeled with 100 ⁇ Ci of Na 2 51 CrO 4 and washed with RPMI.
- the effector cells of the CD8+ T-line were added under the same conditions as described for the astrocytoma cells.
- FIG. 2 shows the results of the proliferation of the anti-IE1 clone BeA3G9 in the presence of PBMC incubated with the purified recombinant antigen GST-IE1-pp65.
- the clone proliferated specifically since no incorporation of thymidine was observed in the presence of protein GST.
- This proliferation was of the same extent as the proliferation obtained with the fusion protein GST-e4 (C-terminal 80% of IE1) or GST-IE1.
- FIG. 3 shows the result of a cytotoxicity test carried out in the context of the infection of U373MG astrocytoma cells of the phenotype HLA-A2.
- a specific lysis of the targets was observed in the presence of peptide N9V (HLA-A2), while this is virtually zero with peptide I9Y (HLA-B35), which demonstrates that the class I MHC molecules of the phenotype A2 at the surface of the U373MG cells are charged specifically with peptide N9V.
- HLA-A2 peptide N9V
- HLA-B35 peptide I9Y
- protein pp65 which has been provided by the inoculum, has been delivered into the cytosol and prepared in such a way that a peptide identical to, or of a similar structure to, N9V was generated and presented specifically to the cells of the line “Val”.
- the purified fragment IE1-pp65 (Example 1, para. 1-2-2) was inserted into the BglII site of plasmid pAcHLT-B (Pharmingen) which contains a sequence coding for a peptide of 6 histidine residues (His 6 ).
- the recombinant plasmids were characterized and purified.
- Sf9 insect cells (ATCC CRL1711) were incubated for 4 hours at 37° C. in the presence of a mixture containing 3 ⁇ g of plasmid and 0.5 ⁇ g of viral DNA according to the protocol provided by Pharmingen. After 5 days of culture, the protein production was analyzed by a “western blot” using monoclonal antibodies against IE1 (E13, Argene) and against pp65 (NEA20, Biosoft).
- FIG. 6 shows the SDS-PAGE analysis of the protein His 6 IE1-pp65 which had been produced by cells infected with recombinant baculoviruses and purified by Ni chromatography.
- the IE1-pp65 formulations were obtained by coincubating for 1 hour at ambient temperature the protein solution (200 nM in PBS with 2.5 mM Na 2 HP0 4 /NaH 2 PO 4 , 62 mM NaCl, 0.65 mM KC1+10% glycerol) and type L SMBV (1 mg/ml in distilled water) at a protein/biovector weight ratio of 7.7 and a protein/nucleus weight ratio of 10.
- the L-type SMBV which is described in WO 94/20078, comprises an external double layer composed of DPPC/cholesterol.
- PBMC Peripheral blood mononuclear cells
- val CMV+donor of the haplotype DR3,13
- Falcon 24-well-plates
- the soluble or formulated antigen IE1-pp65 was added, and the mixture was incubated for 3 days at 37° C.
- 1 ml of culture medium is replaced by 1 ml of fresh medium supplemented with 10% Lymphocult (100 U/ml, Biotest, France).
- FIG. 7 shows the proliferation of anti-IE1 effectors generated from PBMC of the “Val” donor in the single case where the effectors were induced in the presence of the formulated antigen.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- The present invention relates to novel combinations of proteins and to their use as medicament. More particularly, it relates to the preparation of vaccines against CMV.
- Human cytomegalovirus (CMV), an enveloped virus with a 230 kbp DNA double strand, is the largest virus of the herpesvirus family. Like the other members of this virus family, it exists in latent form and can undergo repeated reactivation steps which lead to a viremia several years after the initial infection. CMV is widely distributed throughout the world and, while being well tolerated by healthy individuals, it is associated with pathologies which frequently have drastic consequences for the fetus and for immuno-depressed patients (transplant, AIDS and cancer patients) (see Review (1)).
- Following a primary infection during pregnancy, the vertical transmission of the virus to the fetus via the placenta leads to complications in the newborn. These are, in particular, sensorial disorders (vision, hearing) and significant mental backwardness which arise during the first few years of the child's life. Infection with CMV is associated with graft rejection in transplant patients (foreign transplants of marrow, kidneys, heart, liver). It constitutes one of the most drastic opportunistic infections in HIV+ patients which, despite antiviral chemotherapy, fall victim to—frequently lethal—pathologies. All these reasons mean that CMV infection raises a substantial public health problem.
- The use of unspecific antivirals, such as Ganciclovir* and Foscarnet* during transplantation causes cytotoxicity problems. The secondary effects frequently require a reduced dosage or termination of the treatment, thus posing the risk of the disorder associated with the viral infection recurring. In certain cases, the intravenous injection of high doses of immunoglobulins has reduced the frequency of pneumopathies and rejections. Attempts at adoptive immunotherapy have been developed by injecting, into recipients, marrow of clones of cytotoxic T-cells which are specific for CMV (2).
- The development of a subunit vaccine would be of enormous importance to future mothers. In fact, it has been demonstrated that maternal immunity which has been acquired prior to conception could protect the newborn babies from the damage of congenital infection (3). The development of an anti-CMV immunity in transplant patients would be an important factor against the development of infection-associated diseases. Vaccination trials with the attenuated virus of the Towne strain were carried out and are being performed on seronegative volunteers and seronegative transplant patients who have received a transplant from seropositive donors (4). In the majority of the cases, the vaccination has reduced the severity of the diseases associated with viral replication. As the pathogenic activity of such vaccines has not definitively been excluded and where the use of live vaccines might cause severe side effects in immunodeficient individuals, novel approaches using recombinant viral proteins in the presence of adjuvants are being developed.
- The importance for public health of developing a vaccine against CMV no longer has to be demonstrated as a result of the problem presented by the congenital infection, which has hitherto been underestimated by the medical community.
- The savings made by developing a strategy of preventing diseases linked to CMV infection in risk patients would be substantial. In fact, estimates of the costs associated with the vaccination of an individual and its taking (serological analyses, vaccine, treatment of minor side effects) show that it would be approximately 50 times less than that of the care with which a newborn is provided which is the victim of congenital infection. CMV infection can be observed in 2/3 kidney transplant patients and more often in other transplant patients. Taking into consideration that the infection is associated with complications in approximately 1/3 of these, the annual costs in addition to the transplantation costs are considerable. Despite the impact of drugs such as Ganciclovir*, the injection of gammaglobulins or the transfer of anti-CMV T-clones on the disease, prevention of the primary infection and reactivation in these patients should be a priority. The benefits of an immunization are obvious at the clinical and at the economic level.
- The applicant has now found that the combination of CMV protein pp65 or a fragment thereof with another hapten or antigen of CMV allows the immune reaction towards this virus to be potentiated, in particular by stimulating the compartments T CD4+ and CD8+ against the virus.
- This is why the present invention relates to a fusion protein, characterized in that it comprises at least part of the cytomegalovirus (or CMV) protein pp65, or of a protein having at least 80% homology with protein pp65, in combination with at least one second peptide fragment derived from CMV.
- Protein pp65 is a CMV matrix protein which is internalized in the cells and delivered into the cytosol at the same time as the virion, very shortly after infection.
- It can be used whole or in the form of one or more fragments; the peptide fragments which make up the chimeric protein preferably have a length of greater than, or equal to, 9 amino acids and cover different HLA class I restrictions. The applicant has shown that a peptide of protein pp65 of a length greater than 9 amino acids can be internalized by a presenting cell and presented to a CD8+ specific T-line by a class I MHC molecule. The importance of constructions which include these peptides and the protein IE1 for vaccination would be linked to the use of antigens which are capable of entering the presenting cell by a unique endocytosis pathway, simultaneously inducing it to a TCD4+ and TCD8+ response.
- The second peptide fragment which is present in the fusion protein is preferably composed of protein IE1 or one of its epitopes, or of a protein having at least 80% homology.
- In fact, the polypeptide sequence of IE1, which is a major regulatory protein of the viral cycle, is highly conserved between the different viral strains. Introduction of this protein into a subunit vaccine would allow the induction of memory CD4+ helper T-cells, which are capable of cooperating with the induction of cytotoxic CD8+ T-cells against pp65 and with the production of antibody against the envelope protein gB, subjected to greater variability (cross help). In fact, it has been shown that most of the neutralizing antibodies which are present in the serum of infected individuals were directed against the viral envelope glycoprotein gB (UL55). This is why protein gB was considered to be one of the most important viral antigens for vaccination. A large number of protocols in which recombinant viruses are used (adenovirus, vaccinia, canarypox) have been developed (5, 6, 7).
- The problems presented by these vaccines are linked either to the pathogenic character of the live viruses or to the fact that they induce too low antibody titers. An alternative is the use of recombinant antigens which are combined with adjuvants. The combination of glycoprotein gB with the chimeric protein IE1-pp65 into one structure allows its conformation to be maintained, which is indispensable for its immunogenicity, would offer a means for stimulating the T and B compartments of the antiviral response. Moreover, activation of the CD4+ T-cells against IE1, which is mediated by the IE1 peptides in combination with class II MHC molecules being recognized, would allow viral replication in the adjacent cells, which are subjected to the effect of TNFγ and TNFα (8) to be controlled. Naturally, these hypotheses are not intended to limit the scope of the invention.
- In particular, use can be made of fragment e4 of CMV protein IE1, or a peptide fragment having at least 80% homology with said fragment e4. e4, or exon 4, which comprises 406 amino acids, is a fragment of protein IE1, which is composed of 491 amino acids.
- According to another advantageous aspect of the invention, the fusion protein comprises a) the fragment delimited by the amino acid residues 162 and 175 of the sequence of protein IE1, or
- b) a peptide fragment having at least 90% homology with said fragment mentioned under a).
- Other epitopes are also suitable for carrying out the invention, such as those mentioned by Davignon et al. (8).
- The fusion protein according to the invention can additionally contain a peptide fragment derived from a microorganism other than CMV and/or any polypeptide fragment which allows it to be purified later from Tag-type sequences; these sequences, which are placed upstream or downstream of the protein of interest allow it to be purified or labeled; the use of β-galactosidase, histidine hexamers (His6) or GST may be mentioned as examples. According to a preferred embodiment, the fusion protein comprises a peptide fragment derived from an enzyme with glutathion-S transferase (or GST) activity.
- The GST protein will make it easier, in particular, to purify the fusion protein from a complex culture medium.
- The invention therefore relates to a chimeric protein GST-IE1-pp65 of 145 kd, which can be prepared inE. coli. Its immunogenicity was demonstrated in vitro by the proliferation of IE1-specific CD4+ T-cell-clones and by the lysis of target cells incubated in the presence of a pp65-specific CD8+ T-line. The applicant has shown that the protein in soluble form and its fragments allow the CD4+ and CD8+ T-compartments of the specific cell response to be stimulated in vitro. These results make this protein the reactant of choice for designing a subunit vaccine.
- The nucleotide sequences which code for a fusion protein as defined hereinabove are also within the scope of the invention.
- The fusion proteins and the corresponding nucleotide sequences can be used as medicament and in particular for the preparation of a vaccine for preventing infections caused by CMV. Such a vaccine will be suitable for inducing an efficient response against a primary infection before the virus has replicated actively.
- In accordance with another aspect, the invention relates to a pharmaceutical composition, characterized in that it contains
- a) at least part of the CMV protein pp65 or of a protein having at least 80% homology with protein pp65, in combination with at least one second peptide fragment derived from CMV, or
- b) nucleotide sequences coding for the peptides mentioned under a).
- In addition to formulation excipients known to the skilled worker, such as stabilizers, preservatives, antioxidants, adapted to suit the route of administration, in particular an injection, the compositions can contain immunity adjuvants. They can also contain other CMV epitopes. Finally, they can be formulated with systems which improve transport and presentation of the molecules to the target cells.
- The proteins can be in the form of various different proteins in the composition; they can also be in the form of a fusion protein as described above; the same applies to the corresponding nucleotide sequences.
- In addition, the composition can contain other epitopes, in particular CMV envelope antigens, such as protein gB.
- In accordance with yet another aspect, the invention relates to a process for the preparation of a fusion protein, characterized in that the following steps are carried out:
- a) a first DNA sequence which codes for at least a part of the CMV protein pp65 is linked with a second DNA sequence which codes for another polypeptide or protein derived from CMV so as to obtain a recombinant DNA sequence which codes for a fusion protein,
- b) the recombinant DNA sequence is introduced into a construction containing the elements required for its expression, and, if appropriate, sequences which code for other polypeptides,
- c) the construction obtained in b) is introduced into host cells which are subsequently cultured under conditions in which the expression system of the fused DNA is functional, so that the fusion protein is produced in the host cell,
- d) the fusion protein produced in the host cell is recovered and purified.
- The host cell which contains a nucleotide sequence coding for a fusion protein, which can be obtained in the process described hereinabove, also comes within the scope of the invention. This host cell can be selected in particular from the group consisting of the bacteria, the viruses, the yeasts and eukaryotic cells, in particular higher eukaryotes.
- Other characteristics and advantages of the invention will become obvious from the examples which follow.
- Reference will be made in these examples to the following figures:
- FIG. 1: Western blot analysis of the expression of protein GST-IE1-pp65.
- Lysates of bacteria which have been transformed with plasmids pGEX 2TK (1) and PGEX 2TK/IE1-pp65 (2, 2′) were subjected to SDS-PAGE and then to a western blot which is visualized by antibodies against GST (A), against IE1 (B) and against pp65 (C). Pre-stained molecular weight markers (Gibco) have been used.
- FIG. 2: Protein GST-IE1-pp65 induces a specific proliferation of the CD4+ T-clone BeA3G9 in the presence of PBMC.
- The cells of clone BeA3G9 were incubated in the presence of irradiated PBMC of the phenotype HLA-DRA8 and GST or GST-IE1-pp65-antigen. Cell proliferation of the clone was determined by the incorporation of [3H]-thymidine, measured in cpm.
- FIG. 3: The anti-pp65 CD8+ T-line “Val” lysis of U373MG astrocytoma cells infected with CMV Towne.
- The CD8+ T-line “Val” which has been generated with the pp65 peptide N9V was used in a51Cr enlargement test in the presence of U373MG cells, either incubated with peptide N9V or with peptide 19Y or infected with CMV Towne (5 moi) for 4 hours and followed by incubation with peptide 19Y. The percentage of specific lysis was calculated as shown in Materials and Methods.
- FIG. 4: Schematic representation of recombinant proteins produced inE. coli.
- The peptide sequences which correspond to the epitopes presented by HLA-DR8, HLA-A2 and HLA-B35 and their locations are shown.
- FIG. 5: The anti-pp65 CD8+ T-line “Val” lysis of B/EBV cells incubated in the presence of the trypsin-pretreated protein GST-IE1-pp65.
- Cells of the line “Val” were used in a51Cr enlargement test in the presence of autologous B/EBV lymphocytes which were untreated or pretreated with chloroquine (Materials and Methods) and the peptides and proteins as shown.
- FIG. 6: Analysis of the production of the protein His6-IE1-pp65 by insect cells infected with a recombinant baculovirus.
- Sf9 insect cells were infected for 48 hours with recombinant IE1-pp65 baculoviruses. The cell lysates (1) were centrifuged, and the supernatant (2) was passed through an Ni-agarose column and the eluates were recovered (3, 4). The different fractions were subjected to SDS-PAGE and stained with Coomassie blue.
- FIG. 7: Induction of anti-IE1 CD4+ T-effectors in a CMV+ donor using formulation SMBV/IE1-pp65.
- PBMCs of a CMV+ donor were stimulated with the protein IE1-pp65 (AG) either in soluble form or formulated with SMBV (AG form) or in the absence of antigen (mock). On day 35, the cells are incubated in the presence of protein solutions with or without the protein IE1 (col). The proliferation of the specific anti-IE1 T-cells was determined by measuring the incorporation of tritiated thymidine.
- Production of the fusion protein in DH5α bacteria
- Materials and Methods
- I-Cloning of IE1 and pp65 cDNAs in PGEX 2TK
- I-1 Preparation of the IE1 and pp65 cDNAs
- I-1-1 IE1-cDNA
- The region of the viral genome containing the sequence which codes for protein IE1 which is located in the Hind III C fragment of the CMV strain Towne was cloned into a plasmid called pRL103. This plasmid was used for transfecting cells of the astrocyte line U373 MG (termed A2 (provided by R. Lafemina, Merck Sharp and Dohme, WestPoint, Pa., USA). These cells were cultured to confluence in RPMI-FCS (RPMI 1640 Glutamax, 1 mM sodium pyruvate, 200 u/ml penicillin, 100 μg/ml streptomycin, 10% decomplemented calf serum). The total RNA of a 3-day culture was prepared following the method of Chomzynski and Sacchi (14). The IEI cDNA was generated by RT-PCR (Kit Super Script, GIBCO BRL) using an aliquot of 5 μg of total RNA, in accordance with the manufacturer's instructions using the primers C1: GATCCGGATCCATGGAGTCCTCTGCCAAGAGA and C2: CCCGGGGAATTCCTGGTCAGCCTTGCTTCTAGT. BamH1 and EcoR1 sites were introduced into the primers C1 (5′-end of IE1) and C2 (3′-end of IE1), respectively. The PCR product thus obtained (1480 bp) was purified on an S400-HR column (PHARMACIA).
- I-1-2 pp65-cDNA
- The cells of a human fibroblast line (MRC5, Mérieux) grown in BME supplemented with 10% fetal calf serum (BME/FCS) were infected with CMV (Towne-strain). After a cytopathic effect was observed, the supernatant containing the virus was recovered and heat-inactivated (60° C., 30 minutes) . The virus particles were harvested by centrifugation (31,000 g, 4° C., 90 minutes) and the capsids were degraded by treatment with proteinase K (BOEHRINGER) (150 μg) in 250 μl lysis buffer (10 mM TrisCl pH 7.5, 1 mM EDTA, 2% sarcosyl) for 30 minutes at ambient temperature. The viral DNA was extracted with phenol/chloroform and then precipitated with absolute ethanol. The DNA pellet was dried and solubilized in 20 μl of water. A fragment corresponding to the pp65 cDNA was obtained by PCR with an aliquot of 2 μl of viral DNA using the primers C3: CCCGGGGAATTCATGGCATCCGTACTGGGTCCC and C4: GAATTCGGATCCTCAACCTCGGTGCTrmGG which were complementary to the 5′ and 3′ ends of the pp65 gene and contained the EcoRI and BamHI sites, respectively. The PCR product (1670 bp) was purified on an S400-HR column (PHARMACIA).
- I-2 Construction of the plasmid pGEX 2TK-IE1-pp65
- I-2-1 Purification of the Bam H1- and Eco R1-digested fragments IE1 and pp65
- The IEI and pp65 cDNA fragments were previously cloned into the BamH1 and EcoRI sites of a pUC18 plasmid. Competent DH5α bacteria (GIBCO) were transformed with 5 to 10 ng of a ligation IEI/pUC18 or pp65/pUC18. The recombinant plasmids were digested with BamH1 and EcoR1. The digestion products were separated by agarose gel electrophoresis and extracted from the gel using the “JetSorb/150” kit (GENOMED).
- I-2-2 Purification of the IE1-pp65 fragment
- An identical quantity of fragments IE1 and pp65 which have been digested with BamH1 and EcoR1 was incubated in the presence of T4 DNA ligase. The reaction mixture was digested with BamH1. The fragments obtained pp65-pp65 (3340 bp), IE1-pp65 (3150 bp) IE1-IE1 (2960 bp) were separated by agarose gel electrophoresis. The fragment IE1-pp65 was extracted from the gel using the “JetSorb/150” kit (GENOMED).
- 1-2-3 Cloning of IE1-pp65 into pGEX 2TK
- Fragment IE1-pp65 was inserted into the BamH1 site of plasmid PGEX 2TK (PHARMACIA). Clones of the recombinant bacteria were stored at −80° C. in PBS, 3.5% DMSO, until used for protein purification.
- II-Production of the fusion protein GST-IE1-pp65
- An aliquot of bacteria which had been frozen at −80° C. was resuspended in 5 ml of LB medium containing ampicillin (Ap, 50 μg/ml) and cultured for 8 hours at 37° C. The culture, which was diluted with 45 ml of the same medium, was continued for 15 hours and taken up in 500 ml of LB+Ap to an optical density (λ=600 nm) of 1. The production of GST-IE1-pp65 was induced by adding IPTG (100 μM) to the culture medium. The bacteria were harvested by centrifugation after 3 hours of culture at ambient temperature and stored at −80° C.
- The bacteria were lysed and the recombinant protein purified by affinity chromatography on a “Sepharose 4-B” column grafted with glutathion (PHARMACIA) according to the manufacturer's instructions.
- The degree of purity of the protein was checked by SDS-PAGE followed by staining with Coomassie blue. The antigenicity of GST-IE1-pp65 was analyzed by western blot using goat antibodies directed against GST (PHARMACIA,
dilution 1/400), and mouse antibodies directed against IE1 (supernatant E13 diluted to 1/10, provided by Dr Mazeron, Hal Lariboisière, Paris) and pp65 (NEA 20 diluted to 1/250, DUPONT). Secondary antibodies coupled to RAG/PO, RAM/PO peroxidase (Nordic) were used at 1/500. The proteins were assayed by the method of Bradford using the “Bio-Rad Protein Assay” kit (BIORAD). The recombinant GST protein was produced and purified. - Results and Discussion
- Purification of G3ST-IE1-pp65
- On average, we have obtained 1 mg of GST-IE1-pp65 protein purified by glutathion chromatography from a culture of 500 ml of DH5a/pGEX 2TK-IE1-pp65. Analysis by electrophoresis under denaturing conditions followed by a western blot with the antibodies anti-GST, anti-IE1 and anti-pp65 using lysates of recombinant bacteria is shown in FIG. 1. A product corresponding to a theoretical mass of 145 kd was revealed by the three antibodies in the samples prepared from recombinant bacteria. The lower-molecular-weight bands recognized by the antibodies are protein degradation products. These results agree with the production of a protein resulting from the fusion GST-IE1-pp65 in these bacteria (FIG. 4). Trypsin proteolysis of the protein was analyzed by SDS-PAGE and shows that the disappearance of the migration band which corresponds to the whole protein correlated with the appearance of a band of a low molecular weight which corresponds to the generation of peptides. Amongst these fragments, and after analysis of the sequence of the protein, a peptide of 15 aa appears which contains the peptide N9V (see “Materials and Methods” and FIG. 4).
- Materials and Methods
- I-Lymphoproliferation test
- Cells (2×104) of a CD4+ T-clone (BeA3G9) restricted by HLA DR8 and specific for an epitope at position 162-175 of the protein IE1 were incubated in 100 μl of RPMI-SH medium with irradiated (2500 rads) antigen-presenting cells (1×105 PBMC) of the same HLA-DR phenotype. These cells were incubated with a dilution series of the recombinant protein. On
day - II-Generation of a CD8+ T-line which is specific for a peptide of protein pp65
- Peripheral blood leukocytes of CMV-seropositive donors of the haplotype HLA-A2 (2×106/ml) were cultured in 24-well-plates in RPMI-SH (2 ml). On
day 3, 100 U/ml of “Lymphocult-T-LF” (BIOTEST, France) were added. On day 7, the live cells were recovered in the ring of a ficoll gradient. These cells (5×105/well) were incubated in the presence of autologous stimulator cells (1.5×106/well) in RPMI-SH (2 ml) supplemented with 10% of “Lymphocult”. The stimulator cells (10×106 cells/ml) were incubated in RPMI in the presence of 30 ug of a peptide presented by HLA-A2 (peptide N9V, FIG. 5, Neosystem, France) for 1 hour at 37° C. and irradiated (2500 rads). The effector cells were restimulated under the same conditions every 7 days. The cytotoxicity of the resulting line “Val” was tested on day 14. The CD8+ phenotype of the line was determined cytofluorimetrically with the monoclonal mouse antibody OKT8. - III-Cytotoxicity test
- III-1 In the context of CMV infection
- U373MG astrocytoma cells of the haplotype HLA-A2 (2×105) at 80% confluence in RPMI/FCS were infected with Towne-CMV virus at 5 pfu/cell in 6-well-plates (10 cm2). After infection for 4 hours, the cells were labeled with 100 μci of Na2 51CrO4 (ICN, France) and washed with RPMI. The autologous effector cells of the CD8+ T-line were incubated with 104 target cells in RPMI/10% FCS (500 μl) for 4 hours at 37° C. Various quantities of effector cells were added to the targets to obtain different effector/target ratios. An alternative treatment was the preincubation overnight at 37° C. of the cells, either with peptide N9V or with a peptide recognized by HLA-B35 (peptide I9Y, FIG. 4, Néosystem, France) at a final concentration of 100 nM.
- The rate of spontaneous enlargement was determined by measuring the radioactivity liberated by target cells which were cultured for 4 hours. The percentage of specific lysis was calculated by using the following formula ([measured radioactivity−spontaneous enlargement/total radioactivity−spontaneous enlargement]×100). The radioactivity is measured on a Cobra-γ-counter (PACKARD). Each measurement is carried out in duplicate.
- III-2 In the presence of the native or trypsin—digested protein GST-IEI-pp65, with or without chloroquine
- The purified protein GST-IE1-pp65 was demineralized in an ultrafiltration centrifuge with “
Centricon 10” filter units (FILTRON), lyophilized and taken up in water and then used in this form or digested with trypsin (TCPK, SIGMA, 200 ng per 900 μg of protein) in a volume of 100 μl of Tris-buffer [100 mM tris-HCl pH 8.0] for 2 hours at 370° C. Aliquots taken before and after digestion were analyzed by SDS-PAGE. - Autologous B-EBV lymphocytes (1×106) which have previously been washed and irradiated (104 rads) were preincubated either with the antigens (1 μM) for 15 hours at 37° C. in RPMI-FCS medium (0.5 ml) in a 48-well plate or in RPMI-FCS 5%/
chloroquine 80 μM (SIGMA) for 30 minutes, before adding the antigens. As an alternative treatment, the cells were preincubated overnight at 37° C. either with peptide N9V or with peptide I9Y at a final concentration of 10 nM. After this incubation had ended, the cells (50,000/ml) were labeled with 100 μCi of Na2 51CrO4 and washed with RPMI. The effector cells of the CD8+ T-line were added under the same conditions as described for the astrocytoma cells. - Results and Discussion
- I-Lymphoproliferation of the CD4+ T-clone BeA3G9 in the presence of GSTIE1-pp65
- FIG. 2 shows the results of the proliferation of the anti-IE1 clone BeA3G9 in the presence of PBMC incubated with the purified recombinant antigen GST-IE1-pp65. The clone proliferated specifically since no incorporation of thymidine was observed in the presence of protein GST. This proliferation was of the same extent as the proliferation obtained with the fusion protein GST-e4 (C-terminal 80% of IE1) or GST-IE1. These results demonstrate that the protein GST-IE1-pp65 was prepared correctly by the HLA-DR8 antigen presenting cells so as to present an IE1 epitope which is recognized by cells of clone BeA3G9.
- II-The anti-pp65 CD8+ T-cells of the line “Val” lyse targets incubated in the presence of the trypsin-directed protein GST-IE1-pp65
- II-1 Line “Val” recognizes a natural peptide generated after infection with CMV
- FIG. 3 shows the result of a cytotoxicity test carried out in the context of the infection of U373MG astrocytoma cells of the phenotype HLA-A2. A specific lysis of the targets was observed in the presence of peptide N9V (HLA-A2), while this is virtually zero with peptide I9Y (HLA-B35), which demonstrates that the class I MHC molecules of the phenotype A2 at the surface of the U373MG cells are charged specifically with peptide N9V. When these cells are infected with CMV, a specific lysis of a level equivalent to that obtained with peptide N9V was observed. This suggests that protein pp65, which has been provided by the inoculum, has been delivered into the cytosol and prepared in such a way that a peptide identical to, or of a similar structure to, N9V was generated and presented specifically to the cells of the line “Val”.
- II-2 B/EBV lymphocytes incubated in the presence of the trypsin-digested protein GST-IE1-pp65 are lysed by the anti-pp65 line “Val” as an effect of the chloroquine-treatment of the cells
- The results of an experiment in which the protein GST-IE1-pp65 did not sensitize targets to lysis by line “Val”, in contrast to a sample of this same fraction which had been predigested with trypsin, are shown in FIG. 5. When the cells were pretreated with chloroquine and incubated in the presence of the trypsin-digested protein, the targets were not lysed. Trypsin digestion of the protein generates a peptide of 15 aa, N15K, which contains peptide N9V (FIG. 4). The lysis shown by the targets in the presence of this hydrolysate suggests that peptide N15K is presented to the line “Val”. Moreover, chloroquine-pretreatment of the cells shows that this peptide has been internalized by the cells and prepared in an endo-lysosome-type compartment which is sensitive to a pH increase.
- Materials and Methods
- Cloning of IE1-pp65 into the expression vector “baculovirus” pAcHLT-B. Cotransfection of Sf9 insect cells with the recombinant plasmid and baculovirus DNA:
- The purified fragment IE1-pp65 (Example 1, para. 1-2-2) was inserted into the BglII site of plasmid pAcHLT-B (Pharmingen) which contains a sequence coding for a peptide of 6 histidine residues (His6). The recombinant plasmids were characterized and purified. Sf9 insect cells (ATCC CRL1711) were incubated for 4 hours at 37° C. in the presence of a mixture containing 3 μg of plasmid and 0.5 μg of viral DNA according to the protocol provided by Pharmingen. After 5 days of culture, the protein production was analyzed by a “western blot” using monoclonal antibodies against IE1 (E13, Argene) and against pp65 (NEA20, Biosoft).
- Production and purification of the protein His6IE1-pp65
- The production kinetics of the protein in the infected Sf9 cells were established from
days 0 to 5 and analyzed by a “western blot”. Lysates of infected cells (lysis buffer:Tris 10 mM, NaCl 130 mM, Triton X-100,NaF 10 mM,NaPi 10 mM,NaPPi 10 mM, pH 7.5, Pharmingen) were applied to an Ni-NTA affinity column (Qiagen) and the protein was eluted with the buffer (NaPO4 50 mM, NaCl 300 mM,glycerol 10%, imidazole 0.5 M, Pharmingen). The degree of purity of the protein was checked by SDS-PAGE and staining with Coomassie blue. - Results
- Purification of the Protein His6IE1-pp65
- FIG. 6 shows the SDS-PAGE analysis of the protein His6IE1-pp65 which had been produced by cells infected with recombinant baculoviruses and purified by Ni chromatography. These results demonstrate that the protein constitutes a substantial part of the total cell proteins and is obtained at a higher degree of purity after chromatography.
- Materials and Methods
- Induction of the CD4+ T-lines in vitro from PBMC of a CMV+ donor and incubated in the presence of the chimeric protein IE1-pp65 either in soluble form or formulated in SMBV (supramolecular biovectors)
- The IE1-pp65 formulations were obtained by coincubating for 1 hour at ambient temperature the protein solution (200 nM in PBS with 2.5 mM Na2HP04/NaH2PO4, 62 mM NaCl, 0.65 mM KC1+10% glycerol) and type L SMBV (1 mg/ml in distilled water) at a protein/biovector weight ratio of 7.7 and a protein/nucleus weight ratio of 10. The L-type SMBV, which is described in WO 94/20078, comprises an external double layer composed of DPPC/cholesterol. Peripheral blood mononuclear cells (PBMC) of a CMV+donor of the haplotype DR3,13 (“Val”) were incubated in 24-well-plates (Falcon) at a density of 4×106 cells in 2 ml of RPMI medium/10% human serum (HS). The soluble or formulated antigen IE1-pp65 was added, and the mixture was incubated for 3 days at 37° C. On
day - 2×104 effector cells are incubated in the presence of 1×105 allogenic PBMC and of a solution of proteins originating from the lysate of astrocytoma cells U373MG which have been transfected with the IE genes (termed A2) and contain the antigen IE1. A lysate of non-transfected cells (termed AO) was used as negative control.
- Results
- Induction of the anti-IE1 CD4+ T-Effectors in a CMV+ Donor from IE1-pp65 Formulations.
- FIG. 7 shows the proliferation of anti-IE1 effectors generated from PBMC of the “Val” donor in the single case where the effectors were induced in the presence of the formulated antigen. This result emphasizes the potentiating effect of the formulation, as has been demonstrated before by Prieur et al (9). These results suggest that under conditions where the frequency of the anti-IE1 CD4+ T-precursors is low as is probably the case with the donor “Val” at the time of removing, the formulation allows those cells which are not stimulated and enlarged when the soluble antigen is used to be stimulated and enlarged. The importance of the use of these formulations for inducing T-effectors in vitro is obvious for the development of transfer protocols, for example for marrow transplantations.
- FIG. 2
- -▪- GST
- -o- GST-IE1-pp65
- FIG. 3
- □ N9V
- □ CMV 4h
- □ I9Y
- FIG. 5
- -▪- I9Y
- -□- N9V
- -- N9V chloroquine
- -o- GST-IE1-pp65
- -♦- GST-IE1-pp65, digested
- -″- GST-IE1-pp65, digested, chloroquine
-
- 1. Alford C. A., and Britt W. J.(1990) Cytomegalovirus. In: Virology, Second Edition, (ed. B. N. Fields, and D. M. Knipe et al.), Raven Press Ltd., New York.
- 2. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, R. C., Agha, M. E., Greenberg, P. D. (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Sciences 257: 238-241.
- 3. Fowler, K. B., Stagno, S., Pass, R. F., Britt, W. J., Boll, T. J., Alford, C. A. (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326: 663-66.
- 4. Plotkin, S., Higgins, R., Kurtz, J. B., Morris, P. J., Campbell, D. A., Shope, T. C., Spector, S. A., and Dankner, W. M. (1994) Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58: 1176-1178.
- 5. Cranage, M. P., Kouzarides, T., Bankier, A., Satchxell, S.; Weston, K., Tomlinson, P and Barrell, B. Identification of the hyman Cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J. 1986, 5: 3057-3063.
- 6. Marshall, G. S., Ricciardi, R. P., Rando, R. F., Puck, J., Ge, R., Plotkin, S. A., and Gonezol, E. An adenovirus recombinant that express the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J. Infect. Dis. 1990, 162: 1177-1181.
- 7. Gonczol, E; Berencsi, K., Pincus, S., Endresz; V., Méric, C., Paoletti E., and Plotkin, S. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine. 1995, 13: 1080-1085.
- 8. Davignon J-L, Castanié P., Allan-Yorke J., Gautier N., Clément D., Davrinche C. (1995) Anti-human cytomegalovirus activity of cytokines produced by CD4+ T cell clones specifically activated by IE1 peptides in vitro. J. Virol 70, 2162-2169 (1996).
- 9. Prieur E, Betbeder D, Niedergang F, Major M, Alcover A, Davignon J-L, Davrinche C. Combination of human cytomegalovirus recombinant immediate-early protein (IE1) with 80nm cationic biovectors: protection from proteolysis and potentiation of presentation to CD4+ T cell clones in vitro. Vaccine, 1996, 14: 511-520.
Claims (7)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9615344 | 1996-12-13 | ||
FR9615344A FR2757169B1 (en) | 1996-12-13 | 1996-12-13 | FUSION PROTEIN COMPRISING ALL OR PART OF THE PP65 PROTEIN OF HUMAN CMV, ESPECIALLY USEFUL IN THE PREPARATION OF A VACCINE |
FR96-15344 | 1996-12-13 | ||
PCT/FR1997/002285 WO1998026074A1 (en) | 1996-12-13 | 1997-12-12 | Fusion protein comprising the whole or part of the pp65 protein of human cmv, useable in particular for preparing a vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020156251A1 true US20020156251A1 (en) | 2002-10-24 |
US6605467B2 US6605467B2 (en) | 2003-08-12 |
Family
ID=9498647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/319,264 Expired - Fee Related US6605467B2 (en) | 1996-12-13 | 1997-12-12 | Fusion protein comprising the whole or part of the PP65 protein of human CMV, useable in particular for preparing a vaccine |
Country Status (7)
Country | Link |
---|---|
US (1) | US6605467B2 (en) |
EP (1) | EP0951554A1 (en) |
JP (1) | JP2001506494A (en) |
AU (1) | AU5489298A (en) |
CA (1) | CA2275340A1 (en) |
FR (1) | FR2757169B1 (en) |
WO (1) | WO1998026074A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050054107A1 (en) * | 2003-07-11 | 2005-03-10 | Chulay Jeffrey D. | Alpha virus-based cytomegalovirus vaccines |
WO2006110728A2 (en) * | 2005-04-12 | 2006-10-19 | The Uab Research Foundation | Immunogenic cmv tegument aggregates |
EP1799255A1 (en) * | 2004-06-25 | 2007-06-27 | MedImmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
US20090075384A1 (en) * | 2007-06-21 | 2009-03-19 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562345B1 (en) | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
FR2757169B1 (en) * | 1996-12-13 | 1999-03-05 | Inst Nat Sante Rech Med | FUSION PROTEIN COMPRISING ALL OR PART OF THE PP65 PROTEIN OF HUMAN CMV, ESPECIALLY USEFUL IN THE PREPARATION OF A VACCINE |
DE19910044A1 (en) * | 1999-03-08 | 2000-09-14 | Bodo Plachter | Viral particles released after infection by human cytomegalovirus and their use as a vaccine |
ATE497971T1 (en) | 1999-06-04 | 2011-02-15 | Florian Kern | PEPTIDES FOR VACCINATION AGAINST HUMAN CMV |
CA2403681A1 (en) * | 2000-03-21 | 2001-09-27 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
EP1612217A3 (en) * | 2000-03-27 | 2006-01-18 | City of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
AU2001264764A1 (en) | 2000-05-31 | 2001-12-11 | Genzyme Corporation | Therapeutic anti-melanoma compounds |
AU2002214624A1 (en) | 2000-10-20 | 2002-05-06 | City Of Hope | Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150 |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
TWI810589B (en) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | Human cytomegalovirus gb polypeptide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994000150A1 (en) * | 1992-06-25 | 1994-01-06 | City Of Hope | Induction of cytolytic t-lymphocytes with cytomegalovirus polypeptides |
US5997878A (en) * | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
IT1266740B1 (en) * | 1994-07-01 | 1997-01-14 | Maria Paola Landini | RECOMBINANT PROTEIN MATERIAL BINDING ANTIBODIES AGAINST HUMAN CYTOMEGALOVIRUS, DIAGNOSTIC REAGENTS DERIVED FROM THIS |
EP0702083A3 (en) * | 1994-07-26 | 1997-01-15 | Biotest Ag | Polypeptides and fusion proteins that contain the UL57 open reading frame or the C-terminus of tegument protein pp150 from HCMV, corresponding oligonucleotides and diagnostic test kits |
DE4426453C1 (en) * | 1994-07-26 | 1995-11-02 | Biotest Ag | New fusion protein contg. fragments of two cytomegalovirus antigens |
FR2723849B1 (en) * | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | PROCESS FOR INCREASING IMMUNOGENICITY, PRODUCT OBTAINED AND PHARMACEUTICAL COMPOSITION |
US5800981A (en) * | 1996-02-22 | 1998-09-01 | University Of Limburg | Human cytomegalovirus antigen and its use |
FR2757169B1 (en) * | 1996-12-13 | 1999-03-05 | Inst Nat Sante Rech Med | FUSION PROTEIN COMPRISING ALL OR PART OF THE PP65 PROTEIN OF HUMAN CMV, ESPECIALLY USEFUL IN THE PREPARATION OF A VACCINE |
-
1996
- 1996-12-13 FR FR9615344A patent/FR2757169B1/en not_active Expired - Fee Related
-
1997
- 1997-12-12 WO PCT/FR1997/002285 patent/WO1998026074A1/en not_active Application Discontinuation
- 1997-12-12 CA CA002275340A patent/CA2275340A1/en not_active Abandoned
- 1997-12-12 AU AU54892/98A patent/AU5489298A/en not_active Abandoned
- 1997-12-12 US US09/319,264 patent/US6605467B2/en not_active Expired - Fee Related
- 1997-12-12 JP JP52631998A patent/JP2001506494A/en active Pending
- 1997-12-12 EP EP97951322A patent/EP0951554A1/en not_active Withdrawn
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050054107A1 (en) * | 2003-07-11 | 2005-03-10 | Chulay Jeffrey D. | Alpha virus-based cytomegalovirus vaccines |
US7419674B2 (en) * | 2003-07-11 | 2008-09-02 | Alpha Vax, Inc. | Alpha virus-based cytomegalovirus vaccines |
EP1799255A1 (en) * | 2004-06-25 | 2007-06-27 | MedImmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
EP1799255A4 (en) * | 2004-06-25 | 2008-10-01 | Medimmune Vaccines Inc | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
WO2006110728A2 (en) * | 2005-04-12 | 2006-10-19 | The Uab Research Foundation | Immunogenic cmv tegument aggregates |
WO2006110728A3 (en) * | 2005-04-12 | 2007-12-06 | Uab Research Foundation | Immunogenic cmv tegument aggregates |
US20090075384A1 (en) * | 2007-06-21 | 2009-03-19 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
US7850977B2 (en) | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
US8460913B2 (en) | 2007-06-21 | 2013-06-11 | Alpha Vax, Inc. | Promoterless cassettes for expression of alpha virus structural proteins |
Also Published As
Publication number | Publication date |
---|---|
WO1998026074A1 (en) | 1998-06-18 |
EP0951554A1 (en) | 1999-10-27 |
AU5489298A (en) | 1998-07-03 |
FR2757169A1 (en) | 1998-06-19 |
FR2757169B1 (en) | 1999-03-05 |
JP2001506494A (en) | 2001-05-22 |
US6605467B2 (en) | 2003-08-12 |
CA2275340A1 (en) | 1998-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6605467B2 (en) | Fusion protein comprising the whole or part of the PP65 protein of human CMV, useable in particular for preparing a vaccine | |
US5552143A (en) | Recombinant cytomegalovirus vaccine | |
AU2001249243B2 (en) | Immuno-reactive peptide CTL epitopes of human cytomegalovirus | |
Liu et al. | T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice | |
US7442377B2 (en) | Protective antigen of epstein barr virus | |
CA2160583A1 (en) | Recombinant cytomegalovirus vaccine | |
US20010006639A1 (en) | Immunogenic peptides from the HPV E7 protein | |
JPH11500014A (en) | Viral preparations, vectors, immunogens, and vaccines | |
WO1994017810A1 (en) | Recombinant cytomegalovirus vaccine | |
WO2006110728A2 (en) | Immunogenic cmv tegument aggregates | |
US9517261B2 (en) | Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes | |
JP2013527758A (en) | Vaccines against beta-herpesvirus infection and use thereof | |
CA2308118A1 (en) | Immuno-reactive peptide ctl epitopes of human cytomegalovirus | |
EP0882132B1 (en) | A human cytomegalovirus combined antigen and its use | |
JP2022504624A (en) | Epstein-Barr virus-like particles with enlarged antigenic spectrum | |
US5833991A (en) | Glycine-containing sequences conferring invisibility to the immune system | |
EP1200594B1 (en) | Protective antigen of epstein barr virus | |
US20040191761A1 (en) | Modified adenoviral E1A constructs and methods of use thereof | |
Khyatti et al. | Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC | |
Mili | spontaneous proliferation value of 364 cpm. Thus, the low subunit antigen concentrations in the bivalent subunit vaccine, induced satisfactory humoral and cellular immune responses to HSV1 and HSV2 in the vaccinated mice. Key words: glycoprotein antigens, HSV1, HSV2, humoral and | |
AU2017204774A1 (en) | Vaccine against beta-herpesvirus infection and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRIEUR, ERIC;LULE, JACQUELINE;DAVIGNON, JEAN-LUC;AND OTHERS;REEL/FRAME:010068/0413 Effective date: 19990611 |
|
AS | Assignment |
Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRIEUR, ERIC;LULE, JACQUELINE;DAVIGNON, JEAN-LUC;AND OTHERS;REEL/FRAME:010571/0245 Effective date: 19990611 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20070812 |